FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents

Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.)

Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.) patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

Related Categories:

Drug, Bio-affecting And Body Treating Compositions


Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.)



Erg monoclonal antibodies
12/18/14 - 20140370023 - Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In...

Methods of treating pain by inhibition of vgf activity
12/18/14 - 20140370024 - The present disclosure relates to a method of treating pain, in particular neuropathic pain, comprising administering a therapeutically effective amount of an inhibitor of VGF activity resulting from binding of VGF or a peptide of the type TLQP-21 to the receptor qC1qR. The disclosure also relates to and methods of...

Uses of mammalian cytokines and agonists; related reagents
12/18/14 - 20140370025 - Provided are methods of treatment for tumors. In particular, provided are methods of using of a cytokine molecule and its receptor....

Cytomegalovirus surface protein complex for use in vaccines and as a drug target
12/18/14 - 20140370026 - Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130...

Neuregulin antibodies and uses thereof
12/11/14 - 20140363438 - The invention provides anti-neuregulin1 antibodies and methods of using the antibodies in treating diseases or disorders, such as cancer. In a particular embodiment, the anti-neuregulin1 antibodies bind to both neuregulin1α and neuregulin 1β isoforms....

Anti-lrp6 antibodies
12/11/14 - 20140363439 - The invention provides anti-LRP6 antibodies and methods of using the same. A particular aspect of the invention provides for bispecific anti-LRP6 antibodies that inhibit signaling by multiple Wnt isoforms....

Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases
12/11/14 - 20140363440 - Anti CMV antibodies are provided. Thus an antibody of the present invention comprises an antigen recognition domain capable of binding an MHC molecule being complexed with a cytomegalovirus (CMV) pp65 or pp64 peptide, wherein the antibody does not bind said MHC molecule in an absence of said complexed peptide, and...

Applications of an immune system-released activating agent (israa)
12/04/14 - 20140356368 - The present invention relates to applications of an immune system-released activating agent (ISRAA) polypeptide, which is induced by a nervous stimulus and which has been found to mediate the transmission of signals between the immune system and the nervous system following an immune challenge. Here, the ISRAA polypeptide is for...

Antibodies to human gdf8
12/04/14 - 20140356369 - The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or...

Method of treating and reducing the risk of acute myelogenous leukemia
11/27/14 - 20140348840 - The present invention relates to methods and compositions for treating and reducing the risk of Acute Myelogenous Leukemia (AML). In particular, the invention provides methods for identifying novel treatments for AML based on reproducible and detectable changes in AML1-ETO acetylation. The present invention further provides methods of using these treatments....

Anti-gitr antibodies
11/27/14 - 20140348841 - Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders....

Tim-3 ligands and methods thereof
11/27/14 - 20140348842 - The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a...

Apoe immunotherapy
11/27/14 - 20140348843 - The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases....

Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
11/27/14 - 20140348844 - This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof....

Anti-human cd52 immunoglobulins
11/20/14 - 20140341910 - The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells...

Prevention and treatment of amyloidogenic disease
11/20/14 - 20140341911 - The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is...

Monoclonal antibodies directed to cd52
11/20/14 - 20140341912 - The invention provides antibody to canine or feline or equine antigens, e.g., canine CD52, and methods of making and using antibodies as described....

Methods and compositions for treating asthma using anti-il-13 antibodies
11/20/14 - 20140341913 - The invention provides methods and compositions for treating asthma, e.g., mild or moderate asthma, in a subject using an anti-IL-13 antibody, or antigen-binding portion thereof....

Isolated mcpip and methods of use
11/20/14 - 20140341914 - A monocyte chemoattractant protein (MCP-1)-inducible protein, MCPIP, its polynucleotide and amino acid sequences from mouse and human, and methods for its use are disclosed....

B7-h6 therapeutically active monoclonal antibody against b7-h6 polypeptide
11/20/14 - 20140341915 - The present invention is concerned with diagnostic methods and means. Specifically, it relates to an antibody which specifically binds to a portion of the extracellular domain of the B7-H6 polypeptide. Moreover, said antibody is provided for use in the treatment or diagnosis of cancer or inflammatory disease. Furthermore, provided are...

Therapeutic combinations and methods of treating melanoma
11/20/14 - 20140341916 - The invention provides therapeutic combinations of anti-ETBR antibodies and MAP kinase inhibitors and methods of using the same to treat melanoma....

Anti-pd-l1 antibodies and uses thereof
11/20/14 - 20140341917 - The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and...

Vaccine for falciparum malaria
11/20/14 - 20140341918 - The invention provides compositions and methods for preventing or reducing the severity of malaria....

Pharmaceutical composition for treatment and/or prevention of cancer
11/20/14 - 20140341919 - According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a...

Therapeutic agent for cancer, and method for determining prognosis of cancer
11/13/14 - 20140335090 - Disclosed are a novel therapeutic agent for cancer such as esophageal squamous cell carcinoma, a method for predicting the prognosis of cancer, and a method for detecting, or predicting the prognosis of, cancer such as esophageal squamous cell carcinoma using a sample that can be collected less invasively. The therapeutic...

Anti-glucagon receptor antibodies and methods of use thereof
11/13/14 - 20140335091 - The present invention provides antagonizing antibodies that bind to glucagon receptor and methods of using same. The anti-glucagon receptor antibodies can be used therapeutically to lower glucose levels in blood, and can be in the prevention and/or treatment of glucose-related disorders, including diabetes, hyperglycemia, hyperinsulinemia, impaired fasting glucose, impaired glucose...

Compositions and methods for immunization against drug resistant acinetobacter baumannii
11/13/14 - 20140335092 - The present invention provides vaccine compositions comprising OmpA, or antigenic fragments thereof, and related methods of active immunization against A. baumannii infection. The invention also provides antibodies and antigen-binding parts thereof that specifically bind to OmpA, and related methods of passive immunization against A. baumannii infection. The compositions and methods...

Pd-1 antibodies and pd-l1 antibodies and uses thereof
11/13/14 - 20140335093 - The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof....

Mammalian cytokines; related reagents and methods
11/13/14 - 20140335094 - Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided....

Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response
11/13/14 - 20140335095 - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant or an...

Anti-glucagon antibodies and uses thereof
11/13/14 - 20140335096 - Provided are monoclonal antibodies, or antigen-binding fragments thereof, that bind to glucagon. These antibodies are useful in immunoassays of glucagon levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting glucagon levels, and for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens...

Expression vector
11/13/14 - 20140335097 - The present invention provides an expression vector for cell-surface expression of proteins....

Method for treating metabolic disorders
11/06/14 - 20140328848 - The present invention relates to compositions comprising anti-ActRIIB antibodies and use thereof for increasing brown fat in vertebrate, including rodents and primates, and particularly in humans without significantly affecting hematological parameters....

Anti-crth2 antibodies and methods of use
11/06/14 - 20140328849 - The invention provides anti-CRTh2 antibodies and methods of using the same....

Apelin antigen-binding proteins and uses thereof
11/06/14 - 20140328850 - This disclosure relates to apelin antigen-binding proteins and methods of using the apelin antigen-binding proteins. The antigen-binding protein may comprise an antibody to apelin and can be used to treat pathological conditions involving angiogenesis. The pathological conditions can comprise cancer or retinopathy and/or retinopathy-related complications....

Cholesterol ester transfer protein (cetp) inhibitor polypeptide antibodies for prophylactic and therapeutic anti-atherosclerosis treatments
11/06/14 - 20140328851 - Herein are described two antibodies that can inhibit CETP-lipoproteins interaction and CETP activity. Presently described are an antibody or fragment thereof capable of specifically binding to an epitope of the N-terminal or C-terminal domains of CETP and methods of using these antibodies for separation, identification, diagnosis and therapy....

Immunogenic gluten peptides and uses thereof
11/06/14 - 20140328852 - The invention relates to an immunogenic peptide of eight amino acids that is generated naturally in the intestine of celiac patients by means of the hydrolysis of ingested gluten. In addition, the invention relates to the use of the peptide, or antibodies generated against same, for the in vitro monitoring...

Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
11/06/14 - 20140328853 - Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of organ dysfunction or organ failure. In a preferred...

Compounds and methods for the modulation of beta-1 integrin function to mediate tissue repair
10/30/14 - 20140322222 - The present invention provides methods and compositions that modulate beta 1 integrin activity by functioning as allosteric antagonists. In particular, the present invention provides methods for mediating tissue repair where insult or injury has occurred by antagonising the allosteric function of beta 1 integrin....

Tox3 as a biomarker for breast cancer
10/30/14 - 20140322223 - The invention provides compositions and methods for detecting and/or modulating TOX3 gene expression and/or biological activity. Such compositions and methods find utility in the detection and/or treatment of certain subsets of cancers, e.g. breast cancer. In particular, the inventive compositions and methods are drawn to production and use of anti-TOX3...

Monoclonal antibodies against serotransferrin antigens, and uses therefor
10/30/14 - 20140322224 - The invention relates to monoclonal antibodies (mAbs) that bind to serotransferrin (TF), hybridoma lines that secrete these antibodies or fragments thereof, and the use of these antibodies to detect TF antigens. Methods and uses for detecting prostate cancer, as well as methods and uses for distinguishing early and late stage...

Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
10/30/14 - 20140322225 - In a preferred embodiment anti-ADM antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold according to the present invention reduces the vasopressor requirement, e.g. catecholamine requirement of said patient. The catecholamine requirement of a patient is an indicator for the condition of the circulation and hemodynamic function of...

Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
10/23/14 - 20140314767 - The invention features methods for preventing or treating visceral pain, including pain associated with functional bowel disorder, inflammatory bowel disease and interstitial cystitis, by administering an anti-CGRP antagonist antibody....

Methods and compositions for treating and diagnosing diseases
10/23/14 - - Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in...

Neutralizing antibodies and methods of use thereof
10/23/14 - 20140314769 - This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins,...

Kidney disease targets and uses thereof
10/23/14 - 20140314770 - The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as...

Combination therapy of antibodies against human csf-1r and tlr9 agonist
10/23/14 - 20140314771 - The present invention relates to the combination therapy of antibodies against human CSF-1R with a TLR9 agonist....

Anti-c5a binding moieties with high blocking activity
10/23/14 - 20140314772 - The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention...

Compositions and methods for treating alzheimer's disease
10/23/14 - 20140314773 - The present disclosure provides for a hyperimmune preparation comprising human polyclonal antibodies or fragments thereof specific to a cyclic peptide having an amino acid sequence comprising SNK. The cyclic peptide may comprise an amino acid sequence GSNK (SEQ ID NO: 1), SNKG(SEQ ID NO: 2), GSNKG (SEQ ID N0:3), CSNKG...

Her3 antibodies and uses thereof
10/23/14 - 20140314774 - Provided herein are antibodies specific for HER3. Also provided are methods of treating cancer in a subject comprising administering an effective amount of the antibodies described herein to the subject....

Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment of anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
10/23/14 - 20140314775 - Patients having a chronic or acute disease or acute condition, especially patients at the ICU (Intensive Care Unit) suffer from fluid imbalance. The present invention provides a medicament for regulating the fluid balance and/or improving the fluid balance of such patients. Subject matter of the present invention is an anti-Adrenomedullin...

Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
10/23/14 - 20140314776 - The invention provides a method of treating alveolar bone loss involving administration of a sclerostin inhibitor to a subject in need thereof....

Monoclonal antibodies targeting neutralizing epitopes on h5 influenza virus of clade 2.3
10/23/14 - 20140314777 - The present invention relates to murine monoclonal antibodies C, F and H which target major neutralizing epitopes of influenza H5 hemagglutinin of clade 2.3 and active fragments thereof. The present invention also relates to methods and compositions for the prophylaxis and treatment of H5N1 influenza using murine monoclonal antibodies C,...

Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
10/16/14 - 20140308288 - An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been elucidated and vectors and cells containing and expressing these sequences have been...

Extracellular histones as biomarkers for prognosis and molecular targets for therapy
10/16/14 - 20140308289 - Hyper-inflammatory responses can lead to a variety of diseases including sepsis. It is now shown that extracellular histones released in response to inflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death during sepsis. As such, they can be targeted pharmacologically by inhibitors, as well as used as...

Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
10/16/14 - 20140308290 - The invention features methods for preventing or treating visceral pain, including pain associated with functional bowel disorder, inflammatory bowel disease and interstitial cystitis, by administering an anti-CGRP antagonist antibody....

Immunogenic composition comprising panton-valentine leukocidin (pvl) derived polypeptides
10/16/14 - 20140308291 - The present disclosure provides immunogenic compositions useful in prevention and treatment of Staphylococcus aureus infection. In particular, the disclosure provides methods of inducing an immune response against a panton-valentine leukocidin (PVL)-expressing S. aureus, methods of preventing or treating S. aureus infections, and composition for preventing or treating S. aureus infections....

Novel antibodies and uses thereof
10/09/14 - - The present invention provides an antibody that recognizes a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 15 in the Sequence Listing and has an anti-arthritic function, or a functional fragment thereof....

Anti-axl antibodies and uses thereof
10/09/14 - 20140302041 - The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region...

Methods of predicting prognosis in cancer
10/09/14 - 20140302042 - A set of biomarkers (e.g., genes and gene products) that can accurately inform about the risk of cancer progression and recurrence, as well as methods of their use are disclosed....

Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
10/09/14 - 20140302043 - The invention features a novel influenza antibody that specifically binds to influenza hemagglutinin and reduces or inhibits hemagglutinin binding to sialic acid. The invention also provides methods, compositions, and kits featuring the novel antibody and its use in preventing or treating influenza infection....

Mcpip protection against osteoclast production
10/09/14 - 20140302044 - Disclosed herein are methods of treating a patient at risk of developing an inflammatory joint disease. In exemplary embodiments, the method involves inhibiting MCPIP levels in a patient in need, wherein said patient in need is exhibiting pre-arthritic or pre-osteoporotic symptoms....

Igy composition for use in celiac disease
10/09/14 - 20140302045 - The present invention relates to an IgY composition characterized in that said IgY composition contains IgY antibodies, fragments, and/or Fab fragments thereof that specifically bind to a peptide with the amino acid sequence of SEQ ID NO: 1 and to the use of this IgY composition in the therapy of...

Immunological targeting of pathological tau proteins
10/09/14 - 20140302046 - The present invention relates to methods and compositions for treating, preventing, and diagnosing Alzheimer's Disease or other tauopathies in a subject by administering an immunogenic tau peptide or an antibody recognizing the immunogenic tau epitope under conditions effective to treat, prevent, or diagnose Alzheimer's Disease or other tauopathies. Also disclosed...

Thrombin-binding antibody molecules and uses thereof
10/09/14 - 20140302047 - This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin....

Plasma kallikrein binding proteins
10/09/14 - 20140302048 - Plasma kallikrein binding proteins and methods of using such proteins are described....

Anti-gpr49 antibodies
10/09/14 - 20140302049 - Described herein are to antibodies against GPR49 and uses of such antibodies. Various aspects relate to monoclonal, humanized, or fully human antibodies against GPR49, hybridomas or other cell lines expressing such antibodies, nucleic acids and vectors comprising nucleic acids encoding for such antibodies....

Targeting an amphiregulin-derived cell surface neo-epitope
10/09/14 - 20140302050 - Antibodies to an amphiregulin neo-epitope, fragments thereof, and compositions comprising such are provided. Therapies for cancers in which cells thereof express amphiregulin are provided, as well as assays for identifying additional agents useful in such therapies....

Assays, methods and means
10/02/14 - 20140294842 - A novel class of hydroxylases is described having the amino acid sequence of SEQ ID No. 2, 4, 6 and 8, and variants and fragments thereof having HIF hydroxylation activity. The polypeptides of the invention have in particular prolyl hydroxylase activity. An assay method monitors the interaction of the HIF...

Diagnosis and treatment of copd
10/02/14 - 20140294843 - Provided is a method for diagnosing and/or staging COPD based on detection of one or more histone proteins. In some embodiments, the histone protein is an H3.3 protein comprising a post-translational modification. In some embodiments, the histone protein is H2B, H3, H3.3 or H4. Kits for practicing the methods of...

Prion protein antibodies for the treatment of alzheimer's disease
10/02/14 - 20140294844 - The invention relates to a ligand capable of binding PrP at a site within amino acid residues 131 to 153 of PrP, for use in treatment or prevention of impaired synaptic plasticity. The invention also relates to a ligand capable of binding PrP at a site within amino acid residues...

Anti-pleiotrophin antibodies and methods of use thereof
10/02/14 - 20140294845 - The present invention concerns antibodies that neutralize at least one biological activity of pleiotrophin. The antibodies can inhibit cancer cell growth and angiogenesis in vitro or in vivo. The present invention provides for methods of inhibiting cancer cell growth or angiogenesis in a subject comprising administering to said subject an...

Function and regulation of adamts-1
10/02/14 - 20140294846 - The present invention relates to ADAMTS-1 and uses thereof. The present invention also relates to fragments of ADAMTS-1 and methods of inhibiting cell growth and metastasis. The present invention also provide methods of identifying inhibitors and activators relating to the function of ADAMTS-1....

Biological materials related to c-met
10/02/14 - 20140294847 - The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to...

Novel targets for regulation of angiogenesis
10/02/14 - 20140294848 - The present invention relates to the identification of polynucleotides and polypeptides having increased expression in tumor blood vessels. The invention further relates to the use of the identified polynucleotides and polypeptides, and inhibitors of the polynucleotides and polypeptides, in the regulation of angiogenesis and the diagnosis and treatment of angiogenesis-related...

Compositions and uses
10/02/14 - 20140294849 - The invention provides a TLR agonist and an antibody which binds to an antigen such as a β-amyloid antigen for use in stimulating an immune response to the antigen in an individual. The TLR agonist can be delivered at the same time as the antibody, less than 48 hours before...